The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://esmeefuwh925717.wikifrontier.com/8648859/retatrutide_vs_tirzepatide_a_comparative_analysis